Lactobacillus acidophilus surface layer protein A (SLPA) as a therapeutic agent for the treatment of inflammatory diseases

Patent metadata

Field	Value
Publication number	US-11098088-B2
Application number	US-202016790793-A
Country	US
Kind code	B2
Filing date	Feb 14, 2020
Priority date	Oct 24, 2014
Publication date	Aug 24, 2021
Grant date	Aug 24, 2021

Abstract

The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.

First claim

We claim:

1. A method of treating an inflammatory disease of the gastrointestinal system in a subject having said inflammatory disease, the method comprising orally administering a therapeutically effective amount of a recombinant lactic acid bacterium or a composition comprising said recombinant lactic acid bacterium to the subject, wherein the inflammatory disease of the gastrointestinal system is inflammatory bowel disease and said bacterium is:
a) genetically modified to eliminate the display of lipoteichoic acid (LTA) on its surface by eliminating the expression of phosphoglycerol transferase protein, to eliminate the display of surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium and to express surface layer protein A (SlpA) on its surface, wherein the SlpA has the amino acid sequence of SEQ ID NO: 4, the SlpB has the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence at least 95% identical thereto, the SlpX has the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence at least 95% identical thereto, and the phosphoglycerol transferase protein has the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence at least 95% identical thereto; or
b) lacking expression of LTA, SlpB and SlpX on the surface of said bacterium and is genetically modified to express SlpA on its surface, wherein the SlpA has the amino acid sequence of SEQ ID NO: 4, the SlpB has the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence at least 95% identical thereto, the SlpX has the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence at least 95% identical thereto, and the phosphoglycerol transferase protein has the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence at least 95% identical thereto.

2. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.

3. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.

4. The method of claim 1 , wherein said bacterium is genetically modified to eliminate the display of the lipoteichoic acid (LTA) on its surface by eliminating the expression of the phosphoglycerol transferase protein, to eliminate the display of the surface layer protein B (SlpB) and the surface layer protein X (SlpX) on the surface of said bacterium and to express the surface layer protein A (SlpA) on its surface, wherein the SlpA has the amino acid sequence of SEQ ID NO: 4, the SlpB has the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence at least 95% identical thereto, the SlpX has the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence at least 95% identical thereto, and the phosphoglycerol transferase protein has the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence at least 95% identical thereto.

5. The method of claim 1 , said bacterium lacking expression of the LTA, the SlpB and the SlpX on the surface of said bacterium and is genetically modified to express the SlpA on its surface, wherein the SlpA has the amino acid sequence of SEQ ID NO: 4, the SlpB has the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence at least 95% identical thereto, the SlpX has the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence at least 95% identical thereto, and the phosphoglycerol transferase protein has the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence at least 95% identical thereto.

Assignees

• Univ Florida

Inventors

• Lightfoot Yaima L
• Sahay Bikash
• Mohamadzadeh Mansour

Classifications

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K38/164

  from bacteria · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61K38/13

  Cyclosporins · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title